At DeepCovalent, we believe drug discovery should be driven by intelligence, not iteration.

Traditional early-stage drug discovery is slow, costly, and constrained by repetitive trial-and-error processes. Our revolutionary One-Step-DeNovo™ (OS3D™) GenAI Engine transforms this paradigm by generating optimized molecules directly from property requirements — cutting discovery time and cost by over 90%. OS3D™ intelligently navigates vast, unexplored chemical space to identify high-potential drug candidates with unmatched precision and efficiency.

Founded by a team of AI researchers, chemists, and drug discovery scientists, DeepCovalent is headquartered in Boston, MA, and dedicated to partnering with innovators across pharma and biotech to redefine how therapies are discovered and developed.